Podcasts about sativex

Dr. Ethan Russo is a board-certified neurologist, psychopharmacologist, and Founder/CEO of CReDO Science. He is an internationally recognized authority on cannabis medicine. He has authored/edited seven books and has published more than 60 peer-reviewed articles. He also holds director/advisor positions with several cannabis therapeutics companies, and he was instrumental in developing Sativex® for pain and MS, and Epidiolex® for intractable epilepsy while at GW Pharmaceuticals. At CannMed 24, Ethan will present “Cannabinoid Hyperemesis Syndrome (CHS): Unraveling the Gordian Knot”. CHS is an enigmatic condition where some chronic, heavy users of THC develop a cyclic pattern of vomiting and nausea that is only relieved by hot bathing and topical capsaicin. Ethan and his coinvestigators surveyed more than 500 cannabis users, including 205 diagnosed CHS patients, and investigated genetic mutations in 28 CHS patients and 12 controls to identify behaviors and genetic markers that could indicate CHS risk. During our conversation, we discuss:  What is CHS and who does it affect  Why cases of CHS appear to be on the rise  Possible genetic markers that could indicate CHS susceptibility     Steps cannabis users can take to prevent developing CHS  Why some people in the cannabis community don't believe CHS is a real thing and more  Thanks to This Episode's Sponsor: Cannabis Nurses Network Established in 2015, the Cannabis Nurses Network™ is a professional nursing and professional development organization for nurses around the globe. By educating nurses on the science behind the plant and providing a global nursing network, nurses are supported and empowered to implement their knowledge within their community. Learn more at cannabisnursesnetwork.com Additional Resources what-is-chs.com ethanrusso.org CReDO-science.com Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation Unraveling the Mystery of Cannabinoid Hyperemesis Syndrome - CannMed 2019 Panel Register for CannMed 24 What Makes CannMed Unique and Why You Don't Want to Miss It Review the Podcast! CannMed Archive

A short intro for the eminent Dr. Ethan Russo is challenging. Ethan Russo is a neurologist who explored the Amazon rain forest in the 90's to explore medicinal plants with aboriginal tribes. He returned to the USA and became interested in medicinal cannabis. He quickly became an expert in the field, and worked as a consultant for GW Pharmaceuticals. Later, as a Senior Medical Advisor for GW, he was involved with the development of Sativex and Epidiolex.Dr. Russo founded CReDO Science, who create innovative products and services related to cannabis and the endocannabinoid system. Trevor and Dr. Russo discuss Cannabinoid Hyperemesis Syndrome (CHS). It is a relatively rare, but very unpleasant condition that causes some heavy users of cannabis to be very nauseous and vomit a lot. Dr. Russo and collaborators have developed a genetic test that may be able to predict who will get CHS and thus who might want to avoid THC containing cannabis altogether.Then Trevor and Dr. Russo discuss THCV. Come hear about all the potential indications for this lesser known cannabinoid.Make sure you listen to the very, very end of this episode for a hidden my cannabis story.Ethan Russo Website - ethanrusso.orgCannabinoid Hyperemesis Syndrome Survey and Genomic Investigation - articleCHS DNA test - what-is-chs.comMusic by: Nelson Little - High Road - YouTubeAdditional Music:Desiree Dorion desireedorion.comMarc Clement - FacebookTranscripts, papers and so much more at: reefermed.ca

Se video av dette intervjuet på Pusterom.comKostholdsveileder Melissa Thelwall har jobbet med produksjon og salg av cannabidiol-produkter (CBD) siden 2018. CBD-produkter brukes mot en rekke helseplager, og inneholder mindre enn 0,03 % av det psykoaktive stoffet THC. Det betyr at man ikke blir ruset av disse produktene, men som gründer for Mels CBD-produkter, opplever Thelwall mange fordommer. Alt fra Cannabis Sativa-planten, unntatt hempfrøene, regnes som narkotika i Norge. Det er derfor stort stigma knyttet til å bruke det, og mange tør ikke å fortelle om det av frykt for å miste jobben eller bli regnet som en dårlig forelder. Ifølge Thelwall er sprayen Sativex det eneste CBD-produktet som kan brukes lovlig i Norge. Det inneholder lik mengde av THC og CBD, noe som gjør at enkelte klager på at de blir ruset og svimmel. For å få denne sprayen, må man ha prøvd alt som er relevant for diagnosen av syntetiske legemidler, og fastlegen kan deretter skrive en søknad. Thelwall synes det er hårreisende at man må jobbe seg igjennom en lang liste av potensielt avhengighetsskapende medisiner, før man kommer til et naturlig produkt.› MELS CBD Oils› What is CBD (søk)› What is THC (søk)Relatert AJP-episode: • AJP 45 | Aleksander Bjargo – Vi glemmer at vi er en del av naturenLast ned episodenInnspilt: 2023-09-28Publisert: 2023-10-05Støtte Antijantepodden?Liker du arbeidet vi gjør, og vil bidra til at vi lager flere episoder?Finn ut hvordan du kan gi noe tilbake ved å gå til antijantepodden.com!Meld deg på vårt nyhetsbrev

Anesteziologinja asist. dr. Branka Stražišar ima dobre izkušnje z zdravljenjem z medicinsko konopljo. Pravi, da na Onkološkem inštitutu v Ljubljani kanabinoida THC in CBD največkrat predpišejo za zdravljenje bolečine in lajšanje nekaterih pogostih rakavih simptomov. »Pri večini bolnikov se bolečina zmanjša.« V Sloveniji zdravljenje z magistralnimi kapljicami kanabinoidov THC in CBD od letošnjega leta krije zdravstveno zavarovanje. Pri nas pa, za razliko od nekaterih drugih evropskih držav, še ni registriran učinkovit naravni preparat Sativex. Mogoč pa je interventen uvoz za posameznega bolnika. Več v Ultrazvoku. Z dr. Branko Stražišar je govoril Iztok Konc.

A short intro for the eminent Dr. Ethan Russo is challenging. Ethan Russo is a neurologist who explored the Amazon rain forest in the 90's to explore medicinal plants with aboriginal tribes. He returned to the USA and became interested in medicinal cannabis. He quickly became an expert in the field, and worked as a consultant for GW Pharmaceuticals. Later, as a Senior Medical Advisor for GW, he was involved with the development of Sativex and Epidiolex.Dr. Russo founded CReDO Science, who create innovative products and services related to cannabis and the endocannabinoid system. Trevor and Dr. Russo discuss Cannabinoid Hyperemesis Syndrome (CHS). It is a relatively rare, but very unpleasant condition that causes some heavy users of cannabis to be very nauseous and vomit a lot. Dr. Russo and collaborators have developed a genetic test that may be able to predict who will get CHS and thus who might want to avoid THC containing cannabis altogether.Then Trevor and Dr. Russo discuss THCV. Come hear about all the potential indications for this lesser known cannabinoid.Make sure you listen to the very, very end of this episode for a hidden my cannabis story.Ethan Russo Website - ethanrusso.orgCannabinoid Hyperemesis Syndrome Survey and Genomic Investigation - articleCHS DNA test - what-is-chs.comMusic by: Nelson Little - High Road - YouTubeAdditional Music:Desiree Dorion desireedorion.comMarc Clement - FacebookTranscripts, papers and so much more at: reefermed.ca

Hunter Land, PhD is the Vice President of Research & Development at Biopharmaceutical Research Company, one of the few DEA Schedule I, FDA compliant cannabinoid research and development companies. He has 20 years of R&D expertise across 25 different indications, as well as 12 years of cannabinoid-focused research.  Most notably, he was GW Pharma's first full-time R&D employee in the US, where he played a critical role in the development of Epidiolex® and Sativex®, and co-authored multiple protocols for the treatment of refractory epilepsy, multiple sclerosis, and pain. At CannMed 23, Hunter's presentation was titled Effect of Cannabinoids and Cannflavins on Neurodegeneration, Lifespan, and Healthspan, which is the basis for our conversation today. You can find a link to that video in the show description. Topics we discussed include: Defining lifespan, healthspan, and longevity Why C. elegans are good organisms for studying toxicity and longevity Whe entourage effect, more specifically whether a combination of compounds has a greater effect on longevity than single compounds How do cannabis compounds compare to other longevity drugs like metformin and resveratrol Whether cannabis compounds could be used prophylactically for conditions like Alzheimer's and dementiaDetermining the ideal dosing range for cannabinoids Whether CBD and CBG should be incorporated into a healthy lifestyle to improve longevity  Thanks to This Episode's Sponsor - Trulieve Trulieve strives to bring you the relief you need in a product you can trust. Their plants are hand-grown in a facility with a controlled environment specially designed to reduce unwanted chemicals and pests, keeping the process as natural as possible at every turn. Their mission is to provide compassionate care patients can trust when traditional medicine is not enough. Their specially-trained staff works hand-in-hand with YOUR physician to provide the right products and the correct dosage to ensure you get the compassionate care you need. To learn more visit trulieve.com Additional Resources Effect of Cannabinoids and Cannflavins on Neurodegeneration, Lifespan, and Healthspan - Hunter Land (CannMed 23 Presentation Video) Biopharmaceutical Research CompanyReview the Podcast!CannMed ArchiveCannMed Community Board [Facebook Group]

In this episode, we talk about altered sensations. So what are altered sensations then? They are a bunch of sensory symptoms that can occur in MS, such as burning, tingling, pins and needles, crawling, numbness, prickling and the list goes on!  We talk to Dr Amanda Howarth, a pain specialist about what exactly they are and why they happen. We also share some of the MS community's life hacks around living with altered sensations.Episode notes: - MS Trust A-Z page on altered sensations: mstrust.org.uk/altered-sensations - MS Trust A-Z page on pain: mstrust.org.uk/pain - MS Trust Blog - What's with the strange tingling, crawling, burning and prickling feelings?: mstrust.org.uk/news/expert/whats-strange-tingling-crawling-burning-and-prickling-feelings- MS Trust A-Z on Complementary and alternative medicine: mstrust.org.uk/complementary-and-alternative-medicine- MS Trust A-Z on Cannabis: mstrust.org.uk/cannabis- MS Trust A-Z on Sativex: mstrust.org.uk/sativex- MS Trust A-Z on Gabapentin: mstrust.org.uk/gabapentin

Dirk Nielandt is schrijver van meermaals bekroonde kinderboeken en scenario's, waaronder Sesamstraat, Code 37, Witse, Aspe en Familie. Maar zijn laatste boek ‘Chronisch genezen: goed leven met Multiple sclerose, een helende reis' is geen fictie. Hij schrijft over zijn eigen leven na zijn diagnose met MS. Over zijn zoektocht om zijn eigen gezondheid weer in handen te krijgen. Het boek is een ware bijbel geworden over de aanpak van het hele auto-immuunspectrum, niet alleen Multiple Sclerose. Contact: Info@dirknielandt.be. Verloop van aflevering: Begin – 14: Intro en diagnosestelling van Dirk Nielandt 14 - 30: Begin van de helende reis: voeding, discussie vlees/geen vlees (Wahls vs Jelinek), brood (gluten & tarwe) 30 - 35: Medicatie & immuniteit, Sativex & CBD 35 - 50: Immuniteit & darmbacteriën 50 - 53: Intermittent fasting 53 - 60: Beweging & yoga, andere therapieën 60 – 65: Spiritualiteit 65 – einde: outro Aangehaalde literatuur en links: Meer informatie? Boek: Chronisch genezen: een helende reis (een hele selectie boeken terug te vinden in het boek) Servaas Bingé: De Lijst Tom O'Bryan: The Autoimmune fix Over voeding: - het Wahls-protocol (met MS en vork) - Overcoming MS - MS Hope Facebook pagina Chronisch Genezen: https://www.facebook.com/groups/733021151354905 Vragen over MS? MS-liga Vlaanderen ------------------------------------------------------ De host van de LifeMe podcast is Len De Nys: Instagram: @denyslen Twitter: @LenDeNysLife Site: https://lendenys.eu/ ------------------------------------------------------ Verder staat het hele LifeMe team ook steeds voor je klaar om vragen te beantwoorden en voor goede doorverwijzingen: info@lifeme.be. Facebook: @LifeMeBelgium Instagram: @lifeme_vzw Site: www.lifeme.be

What's wrong with the cannabis industry?Joining us again on the latest episode of The Cannabis Conversation is Dr Ethan Russo, Founder of Credo Science -  a novel medical science company.We discuss the prejudice and ignorance against Cannabis, as well as safety monitoring, legalisation and some of the challenges the industry is facing, including a lack of proper funded research in the area.The Cannabis Conversation is sponsored by Lumino - a boutique HR and Recruitment Agency specialising in building high performance teams for the European Cannabis Industry. They work in three main verticals: Commercial, Medical and Plant Facing.Get in touch at www.luminorecruit.com/About Ethan RussoEthan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Founder/CEO of CReDO Science https://credo-science.com He is also Medical Director of Andira Pharmaceuticals Andira – Bringing Healing to Life and Senior Medical Advisor to Canurta Home | CanurtaPreviously he was Director of Research and Development for the International Cannabis and Cannabinoids Institute, 2017-19, Medical Director of PHYTECS, 2015-2017, and from 2003-2014, Senior Medical Advisor, medical monitor/study physician to GW Pharmaceuticals for numerous Phase I-III clinical trials of Sativex® and Epidiolex®.He was a clinical neurologist in Missoula, Montana for 20 years. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, and in Medicine at the University of Washington. He is author/editor of seven books and has published more than 50 peer-reviewed articles.ResourcesJoin Dr. Russo on LinkedIn: https://www.linkedin.com/in/ethan-russo-md-468b19a/View Dr. Russo's clinical research papers: https://www.researchgate.net/profile/Ethan_RussoCReDO Science Website: https://credo-science.com/

Dr. Ethan Russo and Nishi Whiteley have worked together for almost 10 years in efforts to:improve the scientific understanding of the endocannabinoid system (ECS) and how the cannabis plant modulates itassist small and large cannabis companies in product formulationadvise companies on cannabis genetics enhancementsconsult on pre-clinical and clinical research design.“We share a vision of making cannabis better and safer believing in a future in which knowledge of the endocannabinoid system and its therapeutic modulation via the cannabis plant will result in superior highly individualized medicines, aids to wellness, enhanced lifestyles, and novel non-toxic industrial products”.Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and author. He is the Founder and CEO of CannabisResearch.org. Previously, he was Director of Research and Development at the International Cannabis and Cannabinoids Institute (ICCI) based in Prague, Czech Republic. Medical Director of PHYTECS (2015-2017), a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system, and from 2003-2014, he served as Senior Medical Advisor, medical monitor, and study physician to GW Pharmaceuticals, United Kingdom for numerous Phase I-III clinical trials of Sativex® for alleviation of cancer pain unresponsive to optimized opioid treatment and initial studies of Epidiolex® for intractable epilepsy.Nishi Whiteley (pronounced Nee-sha), is the co-founder and Chief Operating Officer at CReDO. She has twenty-five-plus years of international business development experience in cannabis, agriculture, wellness, green energy, and food industries. She has had leadership roles on projects in corporate America and for the US Foreign Ag Service in over 10 countries, in startups, a state agency, and non-profits; as well as worked for foreign governments and met with international leaders in Cuba, Mexico, and the Dominican Republic to open trade and advance development programs. She has worked on investment projects in 8 countries.

LJ Amaral is a Clinical and Research Dietitian specializing in Oncology at Cedars-Sinai Hospital in Los Angeles. She is currently doing research on the ketogenic diet as an adjunct treatment to the standard of care for brain cancer patients. Find LJ at https://www.ljamaral.com Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and former Senior Medical Advisor to GW Pharmaceuticals. He served as study physician to GW Pharmaceuticals for three Phase III clinical trials of Sativex. He is author of Handbook of Psychotropic Herbs, co-editor of Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential, and author of The Last Sorcerer: Echoes of the Rainforest. He was founding editor of Journal of Cannabis Therapeutics, selections of which were published as books: Cannabis Therapeutics in HIV/AIDS, Women and Cannabis: Medicine, Science and Sociology, Cannabis: From Pariah to Prescription, and Handbook of Cannabis Therapeutics: From Bench to Bedside. He has also published numerous book chapters, and over thirty articles in neurology, pain management, cannabis, and ethnobotany. - - - In this live salon from 9/20/22 on Clubhouse, Ethan, Dr. Russo and LJ discuss the current research and opportunities presented for brain cancer patients when it comes to diet and nutrition, specifically the Ketogenic Diet and the use of cannabis to treat brain cancer. This conversation was hosted with the support of xCures, learn more and signup for their xINFORM platform that pairs patients with clinical trials at www.xcures.com/brain Learn more about LIFECHANGES at www.ourlifechanges.co and the Love Extremist Project at www.extremist.love

La marihuana ayuda a mitigar síntomas de artritis reumatoideLa artritis reumatoide (AR), según la Clínica Mayo, es un tipo de trastorno autoinmune caracterizado por un sistema inmunitario que ataca erróneamente el tejido articular sano y causa inflamación. El ataque comienza en el revestimiento de las articulaciones más pequeñas, como los nudillos, y causa hinchazón y deformidad dolorosa. La inflamación puede luego extenderse a otros tejidos como la piel, los ojos, los pulmones, el corazón y los vasos sanguíneos. A partir de 2014, alrededor de 1.3 millones de adultos padecían AR solo en los EE.UU.Los tratamientos tradicionales para la AR incluyen analgésicos de venta libre, con casos severos que requieren medicamentos opioides para un alivio suficiente. Los corticosteroides como la prednisona también se usan para aliviar temporalmente la hinchazón y la inflamación, pero no se pueden mantener por largos períodos de tiempo sin un riesgo grave de efectos secundarios adversos. Según el Johns Hopkins Arthritis Center, se recomienda una profusión de medicinas complementarias y alternativas (CAM) a los pacientes con AR. Abogan por todo, desde un cambio dietético completo hasta suplementos como aceite de pescado, jengibre, cúrcuma y valeriana. También incluyen opciones como yoga, imanes, acupuntura, hidroterapia, entre otros. Sin embargo, lo que no incluyen es el beneficio de la terapia con cannabinoides.Por qué el Cannabidiol y tetrahidrocannabinol son el equipo ideal para el dolor artríticoUn estudio publicado en el Journal de National Academy of Sciences de Estados Unidos en agosto de 2000 encontró que los síntomas de la artritis inducida por colágeno en ratones se redujeron con la administración de cannabidiol CBD. Determinaron que las capacidades anti artríticas del CBD provienen de sus propiedades inmunosupresoras y antiinflamatorias. Específicamente, determinaron que el CBD puede limitar la respuesta inmunitaria.Otro estudio, del Journal of Rheumatology, evaluó la efectividad de un medicamento llamado Sativex, un aerosol oral con una proporción estandarizada de THC:CBD, en el tratamiento de la AR y se observó un efecto analgésico significativo durante el movimiento y en estado de reposo en el paciente con AR que participó en el estudio. Lo anterior significa que los hallazgos están en línea con estudios mencionados antes, que indica que el CBD reduce la inflamación a través de la inmunosupresión. Además, observaron una mejora en los patrones de sueño de los pacientes tratados con Sativex. Este fue el primer estudio controlado de un cannabinoide en la AR, pero desde luego exige una investigación más profunda sobre esta terapia alentadora y bien tolerada.ADEMÁSPresidente de Uruguay: Nos equivocamos al permitir la venta y compra de marihuanaEl presidente uruguayo, Luis Lacaille Pou, consideró que su país cometió un error al aprobar una ley para legalizar la marihuana y que permite que el Estado sea parte de este comercio.Uruguay fue el primer país del mundo en legalizar la venta y producción de marihuana, en 2013, bajo el mando del presidente izquierdista José Mujica, quien vio en la ley una forma de mantener a sus ciudadanos alejados de las redes del narcotráfico.Desde entonces, se permiten en Uruguay tres formas de obtener marihuana: cultivando en casa para consumo individual, perteneciendo a cooperativas privadas para cultivarlo, o comprándola en farmacias, bajo el control estatal.Pero para el actual presidente, de centroderecha, el Estado no debería ser parte del proceso de cultivo o venta de “drogas” porque son “no rentables”.“Cometimos un error”, dijo y agregó que el sistema está vigente y “es difícil cambiarlo de la noche a la mañana” agregó en declaraciones a la BBC.El presidente uruguayo, aseguró que del dinero de todos los contribuyentes están subsidiando la industria: “porque tenemos que poner algo de dinero mensualmente, anualmente, porque la producción no es sostenible”, comentó./////////Turismo de cannabis es ya una industria de $17 mil millones en Estados UnidosDesde recorridos por granjas de marihuana hasta hoteles, los estadounidenses están descubriendo que el Canna Turismo ya no es sólo para consumidores de marihuana. A medida que se extiende la legalización, la marihuana también se ha vuelto considerablemente menos estigmatizada. Más de dos tercios de los adultos estadounidenses (68%) ahora apoya el uso de adultos, según una encuesta de empresa Harris realizada en mayo 2022. La mitad de todos los millennials (50%) dice que el acceso al cannabis recreativo legal es importante a la hora de elegir un destino de vacaciones, y más de cuatro de cada diez millennials (43%) dice que eligió específicamente un destino, porque el cannabis era legal allí.Por ahora, los viajes de cannabis han sido ignorados en gran medida por las juntas de turismo y la industria, dejando millones de dólares sobre la mesa, dice Victor Pinho, cofundador de Emerald Farm Tours. “Son turistas y están de compras, están aquí para gastar dinero en la meca de la hierba”, dice, explicando cómo su cliente típico gasta entre $300 y $400 en el dispensario durante sus visitas, aproximadamente tres veces más que una transacción promedio con los lugareños, reporta Forbes.No te olvides de suscribirte al podcast y dejar tus comentarios en tu plataforma preferida.Hasta la próxima…Disclaimer Cannabis Hispano no promueve ni participa en actividades ilegales relacionadas con el uso o la venta de marihuana o sus derivados. Tampoco vende o intercambia cannabis por servicios. Consulta a un profesional de la salud si consideras usar cannabis.

Bonus mini episode : 5 reasons Cannabis should be legal in the UK. ************************************** Discussing the reasons why Cannabis should be medically legal in the UK. ************************************** Host: Roxy : https://instagram.com/sickandsickening_podcast⁣ https://instagram.com/multiplesclerosisfashionista⁣ *************************************** MS society UK :  https://www.mssociety.org.uk/about-ms/treatments-and-therapies/cannabis ************************************** Sativex : https://www.mstrust.org.uk/a-z/sativex-nabiximols ************************************* Bridgefarms :  https://www.bridgefarmgroup.co.uk *************************************** Grassroots The Cannabis revolution documentary :⁣ https://youtu.be/mlQ9AFjsVK8⁣ *************************************** Music by : The Apehouse⁣ Instagram :⁣ https://instagram.com/theapehouse⁣ YouTube:⁣ ://m.youtube.com/watch?feature=youtu.be&v=04tDClJqVtc Music directed by : Marcus Siyu⁣ https://instagram.com/seeyu_official.

Episode 323 Wellness Wednesday episode in which we talk about Resources, Sativex, MS Terms, Acute Disseminated Encephalomyelitis ADEM vs MS, does Apple Cider Vinegar expire and other stuff for Multiple Sclerosis Health and MS. Send comments, questions and tips to kevintheduckpool@gmail.com please help us out by rating and reviewing us and telling a friend. Also check out audio and video versions of Crimson Cowl Comic Club & Under the Cowl podcasts. A fun variety of great people talk comic books, entertainment or whatever and you can see or hear me on many episodes of those podcasts as well with many more great episodes to come out in the future. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/kevin-kleinhans/message Support this podcast: https://anchor.fm/kevin-kleinhans/support

Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and author. He is the Founder and CEO of CReDo Science www.credo-science.com In this episode, Dr. Ethan Russo talks to us about his new study on CBG, ‘the mother of all cannabinoids', cannabinoid acids, and affordable diagnostics for the endocannabinoid system that provide needed information for patients and doctors. This technology could improve outcomes and product choices for all phyto-therapies, such as aromatherapy, herbalism, and cannabinoid therapy, which Dr. Russo believes can be much more nimble than one-size-fits-all pharmaceuticals in addressing the individualized needs of the patient. Previously, he was Director of Research and Development of the International Cannabis and Cannabinoids Institute (ICCI) based in Prague, Czech Republic: https://www.icci.science. Medical Director of PHYTECS (2015-2017), a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system (http://www.phytecs.com), and from 2003-2014, he served as Senior Medical Advisor, medical monitor and study physician to GW Pharmaceuticals, United Kingdom for numerous Phase I-III clinical trials of Sativex® for alleviation of cancer pain unresponsive to optimized opioid treatment and initial studies of Epidiolex® for intractable epilepsy (https://www.gwpharm.com). He graduated from the University of Pennsylvania (Psychology), and the University of Massachusetts Medical School, before residencies in Pediatrics in Phoenix, Arizona and in Child and Adult Neurology at the University of Washington in Seattle. He was a clinical neurologist in Missoula, Montana for 20 years in a practice with a strong chronic pain component. In 1995, he pursued a 3-month sabbatical doing ethnobotanical research with the Machiguenga people in Parque Nacional del Manu, Peru. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, Chinese Academy of Sciences, Harvard University, and Johns Hopkins University. He is a Past-President of the International Cannabinoid Research Society and is former Chairman of the International Association for Cannabinoid Medicines. He serves on the Scientific Advisory Board for the American Botanical Council. He is author of Handbook of Psychotropic Herbs, co-editor of Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential, and author of The Last Sorcerer: Echoes of the Rainforest. He was founding editor of Journal of Cannabis Therapeutics, selections of which were published as books: Cannabis Therapeutics in HIV/AIDS, Women and Cannabis: Medicine, Science and Sociology, Cannabis: From Pariah to Prescription, and Handbook of Cannabis Therapeutics: From Bench to Bedside. He has also published numerous book chapters, and over sixty articles in neurology, pain management, cannabis, and ethnobotany. His research interests have included correlations of historical uses of cannabis to modern pharmacological mechanisms, phytopharmaceutical treatment of migraine and chronic pain, herbal synergy and phytocannabinoid/terpenoid, serotonergic and vanilloid interactions. He has consulted or lectured on these topics in 44 US states and Canadian provinces and 44 countries on six continents.Useful Links:https://credo-science.com/projects/CBG StudyCReDoEndo DNA testsEurofins worldwide testinghttps://ethanrusso.org/category/library/ To learn more about plants & your health from Colleen at LabAroma check out this informative PDF: https://mailchi.mp/2fe0e426b244/osw1lg2dkhDisclaimer: The information presented in this podcast is for educational purposes only and is not intended to replace professional medical advice. Please consult your doctor if you are in need of medical care, and before making any changes to your health routine.

On this week's episode, we're joined by Professor Mike Barnes, Neurologist, Director of Maple Tree Consultancy, and Chairman of The Medical Cannabis Clinicians SocietyWe explore the future of Medical Cannabis in the UK by investigating current prescribing practices, stakeholder challenges, and how the government can help develop the industry.→ View full show notes, summary, and access resources here: https://www.canverse.global/shownotes/e135About Professor Mike BarnesProfessor Mike Barnes is a neurologist and cannabis physician. He has worked in cannabis for 20 years, initially with GW Pharma on the first cannabis medicine - Sativex. He oversaw the first UK cannabis prescription for the child Alfie Dingley in 2018 and, after the law change in November 2018, then launched the Medical Cannabis Clinicians Society in November 2018 which now has over 250 clinical members. In 2021 he launched the Cannabis Industry Council with over 100 members across the sector. He runs a medical cannabis consultancy with Hannah Deacon who is the UK's best-known campaigner and mother of Alfie Dingley. He is the Clinical Director of the T21 project.Quotables‘[Cannabis'] medical history is actually more prominent and more robust… than its recreational history' 09:36‘It's down to education. And I think it's Tony Blair that said, education, education, education. And that's the same with cannabis. It's absolutely essential to educate the doctors first, educate politicians after say second, but it's mainly the conservatism of medical professionals holding it back now' 27:45ResourcesThe Medical Cannabis Clinicians Society Website: https://www.ukmccs.org/Professor Barnes' LinkedIn: https://www.linkedin.com/in/michael-barnes-6048b223/Maple Tree Consultants LinkedIn: https://www.linkedin.com/in/michael-barnes-6048b223/#Cannabis Industry Council Website: https://cannabisindustrycouncil.org/Professor Mike Barnes' Website: https://www.profmichaelbarnes.co.uk/

Multiple Sclerosis News Today's columnist, Jenn Powell, discusses a phase 3 trial of Sativex, a cannabis extract, for MS spasticity. Multiple Sclerosis News Today's multimedia associate, Price Wooldridge, reads the column by Ed Tobias, MS Wire, “MS Paralympian Aims for a Bull's-eye”. =================================== Treatment for Relapsing MS Progression | MAYZENT® (siponimod) Read about MAYZENT, a once daily pill that can significantly slow down disability progression in people with relapsing MS. See full prescribing & safety info. https://www.mayzent.com/?utm_source=changeinrms&utm_medium=vanityurl&utm_campaign=novartis_mayzent_2020&utm_content=soundcloud ===================================== Are you interested in learning more about multiple sclerosis? If so, please visit: https://multiplesclerosisnewstoday.com/ ===================================== To join in on conversations regarding multiple sclerosis, please visit: https://multiplesclerosisnewstoday.com/forums/

From malaria to multiple sclerosis, plants have given us compounds which help treat countless conditions. But could a tree growing on your street hold the next life-changing drug?From Madagascar to a Kew Gardens in London, we explore how scientists across the globe use indigenous knowledge and pharmaceutical science to help develop the treatments of tomorrow.And in a world-first, a cannabis-derived drug, known as Sativex, is being trialled in combination with chemotherapy to see if it could be used to help people with a certain type of aggressive brain cancer.The botanical history of medicine (2:04)How do we find the plant medicines of tomorrow? (6:10)The search for a chemical needle in a botanical haystack (9:09)Making drugs: converting cuttings into capsules (14:02)Is it more complex than putting a leaf in a pill? (18:28)Sativex: trialling a cannabis-derived spray on brain cancer (22:50)Do we know how cannabinoids work on brain tumour cells? (26:51)Cannabis and cancer: it's not that simple (28:43)ARISTOCRAT is a randomised phase II study of temozolomide with or without cannabinoids in patients with recurrent glioblastoma.It's being funded by The Brain Tumour Charity and co-ordinated by the Cancer Research UK Clinical Trials Unit at the University of Birmingham.ARISTOCRAT is due to begin recruiting just over 230 patients across all UK nations in early 2022.To learn more about the ARISTOCRAT trial, you can check out:World-first trial tests cannabis-based drug on aggressive brain tumours - University of LeedsGlioblastoma Research: Phase II Clinical Trial of Cannabis Derivatives - The Brain Tumour CharityIf you'd like to talk to someone, our nurses are available Monday to Friday 9-5pm on freephone 0808 800 4040. See acast.com/privacy for privacy and opt-out information.

Sativex to be used in World's 1st Brain Tumor Trial. The Cannabis Oral Spray will be used in an upcoming study led by Leeds University with the help of The Brain Tumour Charity based in the United Kingdom. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Multiple Sclerosis News Today's columnist, Jenn Powell, discusses the first SPMS patient dosed with the nasal spray Foralumab. Multiple Sclerosis News Today's multimedia associate, Price Wooldridge, reads the column by Ed Tobias, MS Wire, “Sativex Study Reports Positive Results in People With MS”. ===================================== Treatment for Relapsing MS Progression | MAYZENT® (siponimod) Read about MAYZENT, a once daily pill that can significantly slow down disability progression in people with relapsing MS. See full prescribing & safety info. https://www.mayzent.com/?utm_source=changeinrms&utm_medium=vanityurl&utm_campaign=novartis_mayzent_2020&utm_content=soundcloud ===================================== Are you interested in learning more about multiple sclerosis? If so, please visit: https://multiplesclerosisnewstoday.com/ ===================================== To join in on conversations regarding multiple sclerosis, please visit: https://multiplesclerosisnewstoday.com/forums/

What is Cannabinoid Hyperemesis Syndrome (CHS)?This week, we welcome back Dr. Ethan Russo, physician, researcher, and leading expert in the field of Medicinal Cannabis. In this episode, Dr Russo shares the latest research and findings of the largest study on CHS to date - in which his team identified 6 potential genetic targets to assist in the diagnosis and treatment of the condition.→ View full show notes, summary, and access resources here: https://www.canverse.global/shownotes/e120About Dr. Ethan RussoEthan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Founder/CEO of CReDO Science https://credo-science.com Previously he was Director of Research and Development for the International Cannabis and Cannabinoids Institute, 2017-19, Medical Director of PHYTECS, 2015-2017, and from 2003-2014, Senior Medical Advisor, medical monitor/study physician to GW Pharmaceuticals for numerous Phase I-III clinical trials of Sativex® and Epidiolex®.He was a clinical neurologist in Missoula, Montana for 20 years. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, and in Medicine at the University of Washington. He is author/editor of seven books and has published more than 50 peer-reviewed articles.ResourcesJoin Dr. Russo on LinkedIn: https://www.linkedin.com/in/ethan-russo-md-468b19a/View Dr. Russo's clinical research papers: https://www.researchgate.net/profile/Ethan_RussoCReDO Science Website: https://credo-science.com/Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation Paper: https://pubmed.ncbi.nlm.nih.gov/34227878/

O uso medicinal da maconha divide opiniões no Brasil e no mundo. Mesmo com a eficácia comprovada para algumas doenças, uma parcela significativa das possíveis utilizações ainda não possui efetivação científica por meio de pesquisas ou está em fase de estudos. Além disso, existe uma preocupação com a padronização da fórmula dos compostos. Dentre os mais de 100 fitocanabinóides, apenas dois são estudados para utilização em remédios – o tetrahidrocanabinol (THC) e o canabidiol (CBD), que estão presentes em maior abundância na planta e são o princípio ativo de medicamentos feitos a partir da Cannabis. Em todo o mundo, o primeiro fármaco aprovado foi o Sativex, um spray bucal utilizado no tratamento de esclerose múltipla e fabricado pela empresa farmacêutica britânica GW Pharmaceuticals desde 2005. Já no Brasil, o remédio é comercializado com o nome de Mevatyl pela Ipsen Farmacêutica, sendo a única medicação derivada de maconha aprovada no país – foi registrado pela Agência Nacional de Vigilância Sanitária (Anvisa) em 2018. Quer saber mais sobre o assunto? Então, ouça agora o novo episódio do Papo Secad! Entrevistamos Rafael Guimarães do Santos, professor de Neurociência e Ciência do Comportamento da Faculdadade de Medicina da USP de Ribeirão Preto, para explicar como são extraídas as substâncias, quais os principais medicamentos, seus usos terapêuticos e as evidências sobre o uso para fins medicinais.

Vettz and G$ are back jumping into the ever so wild medicinal cannabis field. The company they will break down is GW Pharmaceuticals (NYSE: GWPH). They have two products Epidiolex and Sativex both phytocannabinoids synthetically derives from the cannabis plant. You're going to get the full breakdown on financials, how much the stock is, where their products are approved, and mostly importantly if we think this is a great play going forward! Listen up and share this post with your friends on social media @allininvestingpodcast. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Lucy Stafford is no ordinary 20 year old. She's dynamic, intelligent and passionate science student, but growing up, numbed by the increasingly heavy doses of opiates she had received since the age of 12, Lucy believed otherwise.Lucy has Ehlers-Danlos syndrome - a debilitating and extreme painful condition caused by a lack of collagen in connective tissues. Before cannabis, Lucy had resigned herself to a future defined by her disease and the inability of her doctors to manage its symptoms. When Fentanyl, which is fifty times more powerful than heroin, failed to control her pain, Lucy's doctor ran out of options, and in desperation to help his patient attempted to prescribe her Sativex through the NHS. Unfortunately, despite the recent change in the law legalising cannabis based medicines, his request was denied.However, this sowed the seed for Lucy that cannabis might actually help her and she began her own personal journey navigating the illicit cannabis market, eventually getting a legal prescription through a private cannabis clinic.Lucy now gets her cannabis medicine prescription through Project Twenty21, the national registry aiming to get 20,000 medical cannabis patients signed up by the end of 2021.Lucy is also a founding member and patient advocate for PLEA (Patient-led Engagement for Access) and one of the first recipients of the recently launched Cancard - the card scheme started by friend of the show, Carly Barton, that allows to people to verify themselves to police as medicinal cannabis patients.Oh and during lockdown, Lucy has taught herself to walk again (and is regularly walking 5km). Without cannabis, this would never have been possible. Useful links:PLEA Project Twenty21 Cancard The CBD Book: The Essential Guide to CBD OilSupport the show (https://www.paypal.com/paypalme/marybiles71)

How has cannabis and the endocannabinoid system evolved over time?   This week we welcome back the legendary Dr. Ethan Russo, one of the world's leading authorities on medical cannabis and botanical therapeutics, both as a physician and researcher.   This episode, we discuss the origins and evolution of both the cannabis plant and the endocannabinoid system. We also look into how the biochemical diversity of cannabis has been altered by humans over time.View full show notes and summary here: https://www.cannabis-conversation.com/blogs/episode67About Dr. Ethan RussoEthan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and former Senior Medical Advisor to GW Pharmaceuticals. He served as study physician to GW Pharmaceuticals for three Phase III clinical trials of Sativex.He was a clinical neurologist in Missoula, Montana for 20 years in a practice with a strong chronic pain component. In 1995, he pursued a 3-month sabbatical doing ethnobotanical research with the Machiguenga people in Parque Nacional del Manu, Peru. He joined GW as a full-time consultant in 2003.He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, Chinese Academy of Sciences.He is currently Past-President of the International Cannabinoid Research Society, and is former Chairman of the International Association for Cannabinoid Medicines.He is author of Handbook of Psychotropic Herbs, co-editor of Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential, and author of The Last Sorcerer: Echoes of the Rainforest. He was founding editor of Journal of Cannabis Therapeutics, selections of which were published as books: Cannabis Therapeutics in HIV/AIDS, Women and Cannabis: Medicine, Science and Sociology, Cannabis: From Pariah to Prescription, and Handbook of Cannabis Therapeutics: From Bench to Bedside. He has also published numerous book chapters, and over thirty articles in neurology, pain management, cannabis, and ethnobotany. His research interests have included correlations of historical uses of cannabis to modern pharmacological mechanisms, phytopharmaceutical treatment of migraine and chronic pain, and phytocannabinoid-serotonergic and –vanilloid interactions.

What are terpenes and how important are they to the cannabis plant? This week we're joined by Dr. Ethan Russo, physician, researcher, and leading expert in the field of Medicinal Cannabis. In this episode, we discuss all things terpenoid, including how they are produced, varieties commonly found in cannabis, and their therapeutic benefits. Episode SummaryDr. Russo was classically trained as a neurologist, but turned back to a teenage interest in medicinal plants when he realised he was prescribing increasingly toxic drugs to his patients. In the early 90's he became interested in treating headaches and migraines, and took research trips to the Amazon rainforest in Peru to work with native tribes who treated the condition with botanicals.When he returned to the USA he knew that he wanted to change his career path, and became interested in the medicinal properties of essential oils, terpenes and terpenoids.Dr. Russo became interested in using cannabis medicinally and started the Journal of Cannabis Therapeutics. He quickly became an expert in the field, and worked as a consultant for GW Pharmaceuticals who had obtained a permit to grow cannabis for medicinal purposes in 1998.Later on he became a Senior Medical Advisor and was heavily involved with the development of Sativex and Epidiolex.The first cannabis derived pharmaceutical approved by the FDA was Epidiolex, which contains a 98% pure cannabidiol compound and is used to treat Lennox-Gastaut syndrome and Dravet syndrome.To get a drug approved by the FDA often requires between 10 and 12 years of research and between $700m and $1.2bn of expenditure.Dr. Russo has recently founded CReDO Science, who create innovative products and services related to cannabis and the endocannabinoid system, outside the realm of THC. Projects include over the counter treatments, novel extraction techniques, nutritional cannabis products, cannabis based disinfectant, and diagnostic tests. Terpenes are the aromatic components of plants which can be found in the leaves, bark, flowers and sometimes roots. They are used in aromatherapy which is the science of essential oils. An example of this is lemon oil, which denotes cleanliness and is a cleaning agent. The terpene responsible for this aroma is Limonene, which can be found in citrus fruits.Selective breeding for high THC strains means that many of the new strains have a dominant terpene of Myrcene, which interacts with THC to produce sedative effects.Dr. Russo is currently conducting a piece of research which looks into the effects of using THC with differing terpenoids, using memory tests as a measure.There are over 20,000 identified terpenoids, none of which (so far) are unique to cannabis. Alpha Pinene and Limonene are the most abundant in nature but are not found in cannabis very often. In cannabis, Myrcene and Caryophyllene are often found, which interact with CB2 receptors. Caryophyllene is both a terpene and a cannabinoid.In any cannabis sample, there are on average 3-5 prominent terpenoids along with trace amounts of many more.Terpenes act as a defence mechanism for plants, their strong smells either promote pollination, deter predation by insects or to prevent grazing by mammals. Cannabinoids and Terpenoids are both produced in Capitate Glandular Trichomes which are most abundant in unfertilised female plants. Many terpenes have pain reducing effects which work through distinct mechanisms. Quotables‘Terpenes are critical components to the medicinal effects of cannabis' 04:20‘Essential oils are extremely potent, so the amounts involved are tiny' 22:25

Desperate to understand more about my mom's journey, I found Teepa Snow and her Positive Approach to Care. I devoured Teepa's free videos on YouTube, of course read her GEMS book and was eager for more. I signed up for her two-day, in real life Certified Training course and learned how to connect with my mom in a way I thought was no longer possible. When Teepa came to California, I was thrilled that she was willing to sit down and talk about her vast experience with people living with dementia and what she's seen with respect to how cannabis helps or hurts. With her no nonsense style, Teepa likens vanilla extract to CBD - not all are created equal. Teepa reminds us that we don't have other options and asks us to consider “What's the harm?...when pain is unremitting, and sleep won't come...people try things…I have seen remarkable differences...” We touch on a couple of the studies underway around the world, check em out if you like: King's College London will examine if Sativex is effective in treating agitation and aggression in dementia. They will recruit people ages 55-90 living with dementia in care homes. “Sativex® is a peppermint-flavoured mouth spray that contains a 1:1 ratio of two key cannabinoids found in the cannabis plant – delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).” Alzheimer's Society Canada has two studies under way, and this one presented results at the 2018 Alzheimer's Association International Conference in Chicago, IL. http://alzheimersocietyblog.ca/clearing-the-air-about-cannabis-and-dementia/ We hope you find EP2 with Teepa Snow interesting! Please share, subscribe, rate and review to learn more about how cannabis helps dementia. In Solidarity, Chela THANK YOU! Teepa Snow Anchor.fm Society of Cannabis Clinicians Opening music “Wishful Thinking” by Dan Lebowitz ...and thank you Mom, my greatest teacher. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/cannabishelpsdementia/message Support this podcast: https://anchor.fm/cannabishelpsdementia/support

We were once carefree below-the-line film and TV workers: I did props and set dressing and Dave was an Assistant Director and occasional actor. Then we were thrust into family caregiving when my mom was suddenly diagnosed with Alzheimer's Disease. We learned so much from my mother's decade-long journey that I felt we had to share our best practices with other families in crisis. We created AlzNotes.com to provide care gap training and plant based education to others in relationship with dementia. My mom transitioned to Pure Positive Energy in 2019. Cannabis Helps Dementia podcast was born out of my desire to shout from the rooftops how we and others have eased the suffering of loved ones living with dementia by using a medicinal herb where there is no other relief available. You'll hear the science and stories of how cannabis helps ease the difficult behavioral symptoms caused by dementing illnesses. One of the things we learned on this life-changing journey was that the United States Department of Health has held a patent since 1998 specifically for neuroprotection which inspired us to do more research. Patent # 6630507B1 “...cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia…” When we started to get serious about this research, we learned about Dr. Ethan Russo, who is a world renowned neurologist, psychopharmacology researcher, former Senior Medical Advisor to GW Pharmaceuticals (GW created Epidiolex and Sativex, cannabis based medications for epilepsy and MS symptoms) and he is a member of the Society of Cannabis Clinicians. Dr. Russo is a badass rockstar of medical cannabis research and among many other things, he wrote a review article in Frontiers in Integrative Neuroscience, “Cannabis Therapeutics and the Future of Neurology” that really got my attention. Dr. Russo gives the reader an introduction to cannabis medicine, then shows us the studies that have already been done that show how cannabis helps multiple neurological issues including epilepsy, brain tumors, traumatic brain injury, Parkinson's Disease and of course, Alzheimer's. We hope you like EP1 with Dr. Russo. Please share, subscribe, rate and review to learn more about how cannabis helps dementia. In Solidarity, Chela THANK YOU! Dr. Ethan Russo , Anchor.fm , Society of Cannabis Clinicians , “The Scientist” Documentary Opening music “Wishful Thinking” by Dan Lebowitz; montage music “Cartoon Bank Heist” by Doug Maxwell Media Right Productions ...and thank you Mom, my greatest teacher. More reading: Project CBD , “World Health Organization Recommends Reclassifying Marijuana Under International Treaties” Forbes 2/1/2019 article [Full description including glossary coming to CHD website] --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/cannabishelpsdementia/message Support this podcast: https://anchor.fm/cannabishelpsdementia/support

We are excited to announce CannMed 2020's Keynote Presenter in the Science Focus Area is Dr. Ethan Russo. The title of Dr. Russo's presentation is “Cannabis and Psychiatry: The Final Frontier”, and it will explore basic science and clinical trial data to assess the role of cannabis psychopharmacology with respect to issues of impairment, depression, insomnia, PTSD, schizophrenia, anxiety and addiction. You can hear about this fascinating topic and more in our latest episode of the CannMed Coffee Talk Podcast, where Dr. Russo joins us as a guest. This is a great episode for listeners who are new to cannabis medicine because Dr. Russo covers some of the basics, like "what is the endocannabinoid system?" Having said that, there is still plenty of meat on the bone for more advanced listeners. Use the player at the bottom at the post to listen. Dr. Russo began his career as a physician, board-certified in Neurology with a Special Qualification in Child Neurology, but he has always held a strong interest in medicinal plants, which he gradually incorporated into his practice and research endeavors, with the intention of bringing cannabis-based and other botanical agents back into the mainstream of medicine. He is a graduate of the University of Pennsylvania (Psychology) and the University of Massachusetts Medical School, before residencies in Pediatrics in Phoenix, Arizona and in Child/Adult Neurology at the University of Washington, and was a clinical neurologist in Missoula, Montana for 20 years. After his clinical experience, he began dedicating his career to developing innovative approaches targeting the human endocannabinoid system to produce dramatic results for patients suffering from a range of neuro- and immuno-based diseases and disorders. From 2003 to 2014, Dr. Russo was instrumental in developing both Sativex® for pain and MS, and Epidiolex® for intractable epilepsy while at GW Pharmaceuticals. In 2015, he became Medical Director of PHYTECS, a company devoted to the research and development of medicines, supplements and lifestyle approaches to optimizing the function of the endocannabinoid system (ECS), the critical homeostatic regulatory mechanism of human physiology. From 2015-2017, he was Director of Research and Development for the International Cannabis and Cannabinoids Institute. Dr. Russo has also held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, the Chinese Academy of Sciences. He is a Past-President of the International Cannabinoid Research Society, and former Chairman of the International Association for Cannabinoid Medicines. He serves on the Scientific Advisory Board for the American Botanical Council and has published several books, numerous book chapters, and over forty articles in neurology, pain management, cannabis, and ethnobotany, and he has consulted or lectured on these topics in more than 30 US states and 30 countries. His current venture, called CReDO Science, aims to advance cannabis-based and botanical therapeutics via the development of optimized chemovars and extracts, as well as pursuing novel formulations and diagnostics related to the endocannabinoid system. More information can be found by visiting https://credo-science.com. Needless to say, we are delighted to have him as such an important part of CannMed 2020. SIGN UP FOR PODCAST UPDATES AND ENTER TO WIN 2 VIP DINNER TICKETS! Related Links: Ethan Russo, MD CannMed 2018 PresentationEthan Russo, MD ResearchGate ProfileCReDO Science LLC Website

Il caporedattore di Cannabiscienza, il dott. Fabio Turco, cura la rubrica Cannabiscienza News mettendo in esame le pubblicazioni in letteratura scientifica più interessanti del mese con tema Cannabis Medica e Sistema Endocannabinoide. Qui ci presenta un riassunto di questa analisi, parlandoci di: 1) Effetti antidepressivi del Beta-cariofillene Grazie a ricercatori coreani: "Antidepressant-like effects of β-caryophyllene on restraint plus stress-induced depression" https://doi.org/10.1016/j.bbr.2019.112439 2) Fitoterapia tradizionale cinese interagisce con il Sistema Endocannabinoide Grazie a ricercatori cinesi: "Celastrol is a novel selective agonist of cannabinoid receptor 2 with anti-inflammatory and anti-fibrotic activity in a mouse model of systemic sclerosis” https://doi.org/10.1016/j.phymed.2019.153160 3) Cannabinoidi e terpeni per filtrare ed eliminare batteri dall'acqua Grazie a ricercatori pachistani: "Cannabinoids and Terpenes as an Antibacterial and Antibiofouling Promotor for PES Water Filtration Membranes" https://doi.org/10.3390/molecules25030691 4) Profili farmacocinetici dello spray THC:CBD 1:1 sui cani Grazie a ricercatori spagnoli: "Pharmacokinetics of Sativex in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders" https://doi.org/10.3390/biom10020279 5) Il CBG per risolvere l'antibioticoresistenza Grazie a ricercatori canadesi ed egiziani: Questo è l'articolo sviluppato questo mese per le [Cannabiscienza News] dal titolo "Cannabis e antibioticoresistenza: prevenire epidemie globali" https://cannabiscienza.it/pubblicazioni/patologie/cannabis-antibioticoresistenza/ La fonte originale: "Uncovering the Hidden Antibiotic Potential of Cannabis" https://pubs.acs.org/doi/10.1021/acsinfecdis.9b00419#

Medical use The 1998 regulations under the Misuse of Drugs Act 1977 (as amended) listed cannabis, cannabis resin, cannabinol and its derivatives as schedule 1 drugs.[14] For such drugs, manufacture, production, preparation, sale, supply, distribution and possession is unlawful for any purpose, except under licence from the Minister for Health.[15] Licences were granted to GW Pharmaceuticals in 2002 and 2003 to allow medical trials of the cannabis extract nabiximols (Sativex) in a county Cork hospice and Waterford Regional Hospital.[16] In 2014, the 1998 regulations were amended to allow nabiximols to be prescribed by excepting it from schedule 1.[17][18][19] The first licence for medical use of cannabis oil was issued in December 2016 to allow Tristan Forde a two-year-old boy with Dravet syndrome to continue treatment begun in Colorado.[1][20] This was issued by the minister after an application by the boy's physician.[1]weki Reform Luke 'Ming' Flanagan, a longstanding pro-cannabis campaigner, was elected to the 31st Dáil in the 2011 general election as an independent Teachta Dála for Roscommon–South Leitrim.[21] On 6 November 2013, he proposed a motion "That Dáil Éireann calls on the Government to introduce legislation to regulate the cultivation, sale and possession of cannabis and cannabis products in Ireland", which was defeated by 111 votes to 8.[22][23] On 20 November 2013, he introduced a private member's bill, the Cannabis Regulation Bill 2013, which never got a second reading.[24][25] In November 2015, Aodhán Ó Ríordáin, the Minister of State responsible for the National Drugs Strategy, said he favoured decriminalising #cannabis, cocaine and heroin for personal use.[26] Ó Ríordáin lost his seat at the 2016 election. In December 2016, a private member's bill was introduced by Gino Kenny of People Before Profit to make cannabis available in Ireland for medicinal use.[27] It passed second stage without a vote.[2][28] The bill progressed to the amendments stage on 9 November 2017.[29] One of the major organisations campaigning for the legalisation of cannabis in Ireland is NORML Ireland. 'NORML Ireland supports the removal of all penalties for the private possession of cannabis by adults, cultivation for personal use, and the casual nonprofit transfers of small amounts. NORML Ireland also supports the development of a legally controlled market for cannabis'.[30] In June 2018, after a bill was passed to legalise cannabis in Canada, Taoiseach Leo Varadkar stated that the #decriminalisationofcannabis was 'under consideration', with an expert group considering the examining the systems in jurisdictions in which cannabis has been decriminalised for recreational use.[31 weki --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/vegansteven/message

November is National Family Caregiver Month, and while I was at the 4th Annual National Caregiving Conference in Chicago, I met this week's guest, Caregiver Strategist Penny Patnaude. Penny and I talked about some of the things that caregivers want to be thinking about in planning their own strategy for providing great care to their loved one without losing themselves in the process.    I'll also introduce you to Dr. Lindsey Knowles, a young MS rehabilitation researcher who will give us an insider's look at what the Tykeson Fellows Conference is all about, and why it's so important for the future of MS research.   We're also talking about the cannabis-based treatment for MS spasticity that was approved in the U.K. You'll hear about last week's International Progressive MS Alliance meeting in Amsterdam, and we'll tell you about an investigational therapy that can reset the immune system in the mouse model of MS in a single dose.   We'll remind you that if you're a young adult, between 18 and 45 years old, First Descents is offering you a week-long ski trip to Crested Butte, Colorado. And it's FREE! (Don't worry, we'll tell you how and where to begin the application process!)   You'll hear about the research team in Montreal that may have found a way to stop MS progression.   And we'll tell you how easy it is to share this episode of RealTalk MS with family and friends!   We have a lot to talk about! Are you ready for RealTalk MS??! ___________   Thanks for all the kind words!   :22 The National MS Society & RealTalk MS Partnership  :52 Join the Conversation! Get In Touch with RealTalk MS    2:21 The Progressive MS Alliance Meeting in Amsterdam   3:32 The Tykeson Fellows Conference & My Conversation with Dr. Lindsey Knowles  5:26 Sativex Approved in U.K. for MS Spasticity  11:12 Single Dose of Investigational Therapy Resets the Immune System in Mouse-Model of MS  13:19 First Descents Offers a FREE Ski Trip to Crested Butte to Young Adults Living with MS  15:39 Canadian Research Team Says They May Be Able to Stop MS Progression  17:51 My Interview with Caregiver Strategist Penny Patnaude  19:51 Share This Episode  27:11 How to Subscribe to RealTalk MS, Download the RealTalk MS App, or Listen with Alexa  27:36 ___________ SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email:   https://realtalkms.com/117 ___________ ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.comPhone: (310) 526-2283 ___________ LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Give RealTalk MS a Rating & Review  The National MS Society & RealTalk MS Announce a Partnership The International Progressive MS Alliance Administration of a CD45 Antibody Drug Conjugate as a Novel, Targeted Approach to Achieve Immune System Reset: A Single Dose of CD45-targeted ADC Safely Conditions for Autologous Transplant and Ameliorates Disease in Multiple Models of Immune Disease First Descents Skiing at Crested Butte Activated Leukocyte Cell Adhesion Molecule Regulates B Lymphocyte Migration Across Central Nervous System Barriers The Caregiver Strategist Give RealTalk MS a Rating & Review  Download the RealTalk MS App for iOS Download the RealTalk MS App for Android ___________ Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 117 Hosted By: Jon Strum Guests: Penny Patnaude Tags: MS, MultipleSclerosis, MSResearch, MSSociety, Caregiving, Sativex, Stemcells, FirstDescents, RealTalkMS Privacy Policy

On this weeks episode of Off The Strength, the guys catch up with Co-Founder and CEO at RCVR Dan Hunt and discuss his origins and pivotal early realizations in the cannabis industry, life lesson learned from wrestling and jujitsu, how recovery and sleep became a early priority, how start up success came with start up stress, how philosophy plays a role in being able to stay calm in chaos, and role flow plays on his path to success.For Dan and RCVR, catch up with him at:IG: @tryrcvr , @danhuntWeb: https://www.rcvr.com/Be sure to like listen and subscribe! Follow the OTS Squad on IG at:Show - @offthestrength_Tony - @atrainercalledtonyCorey -@yourtrainercoreyKyle - @krjones_Troy - @troy_brooks The Effects Of CBD On Anxiety & StressStudies in humans, including many of those cited below, have demonstrated that CBD reduces anxiety. This is due to the action of CBD on 5HT1A and TRPV1 receptors, both of which are involved in mitigating the anxiolytic, panic and fear responses to stress.Here are the studies that have specifically investigated CBD’s role as an anxiolytic: Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug (PubMed)Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa (PubMed)Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients(PubMed)When it comes to stress, which is of course significantly related to anxiety, the host of studies are just as impressive: Endogenous cannabinoid signaling is essential for stress adaptation (PubMed)Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders (PubMed)Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output(PubMed)This is just a small sample of the research showing the role that CBD plays in reducing stress and reducing anxiety. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress (PubMed)The endocannabinoid system: an emerging key player in inflammation (PubMed)The Effects Of CBD On InflammationCannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress (PubMed)The endocannabinoid system: an emerging key player in inflammation (PubMed)Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice(PubMed)The Effects Of CBD On SleepPatients with sleep issues report that ingesting a CBD-rich tincture or extract a few hours before bedtime has a balancing effect that facilitates a good night’s sleep.Here are the studies on CBD and sleep.Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine (PubMed)Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats (PubMed)Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults(PubMed)Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats See acast.com/privacy for privacy and opt-out information.

Understanding the Pharmacology of Cannabis. Dr. Ethan Russo speaks about the science of Cannabis, Cannabinoids, and Terpenes at the Cannabis Hemp Conference and Expo (CHCE). Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Medical Director of PHYTECS, a biotechnology company researching and developing innovative approaches targeting the human Endocannabinoid system. Previously, from 2003-2014, he served as Senior Medical Advisor and study physician to GW Pharmaceuticals for numerous Phase I-III clinical trials of Sativex® for pain and MS, and initial studies of Epidiolex® for intractable epilepsy. He graduated from the University of Pennsylvania (Psychology) and the University of Massachusetts Medical School, before residencies in Pediatrics in Phoenix, Arizona and in Child/Adult Neurology at the University of Washington. He was a clinical neurologist in Missoula, Montana for 20 years. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, Chinese Academy of Sciences. He is a Past-President of the International Cannabinoid Research Society, and former Chairman of the International Association for Cannabinoid Medicines. He serves on the Scientific Advisory Board for the American Botanical Council. He has published several books, numerous book chapters, and over forty articles in neurology, pain management, cannabis, and ethnobotany. He has consulted or lectured on these topics in more than 30 US states and 30 countries. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/oilycadre/message Support this podcast: https://anchor.fm/oilycadre/support

This week, we warmly welcome Hari Guliani, COO at Grow Biotech to the show! Grow Biotech help to bring medical cannabis products to the UK and research and develop market entry strategies and technologies for medical cannabis producers to create better, cost effective medicines.Together, we discuss the current laws and regulations governing medical cannabis, availability, access to medicine, and hopes for the future. Episode SummaryMedical cannabis was legalised last November in the UK by Sajid Javid, the Home Secretary with the aim to give more UK patients access to cannabis-based medicines. Although technically legal, only a small number of patients have access as it is only prescribed privately and only by specialist consultants who can only prescribe when they see no other options available.Many patients in the UK are incredibly frustrated due to the lack of access, especially since it is not currently supported by the NHS who are concerned with the lack of supporting evidence and the cost of purchase. In August 2019, NICE (The National Institute for Health and Care Excellence) published its draft recommendations on the use of cannabis-based medicinal products following a comprehensive evaluation of their clinical and cost-effectiveness. The review highlighted the lack of evidence about the long term safety and effectiveness of medicinal cannabis.The draft guidance did not recommend Sativex for treating spasticity in people with multiple sclerosis because it was found to be not cost-effective at its current list price in relation to the benefits it provides, although it has been licensed in the UK to treat this problem.If we want to see the widespread adoption of medical cannabis based products within the UK, we need to see the collection of clinical data. This will happen as doctors become more comfortable and informed about cannabis. Because of the rapid expansion of cannabis markets, (recreational and medical), products are often becoming unavailable and cannot be bought consistently. This poses a problem for the UK medical cannabis market as medical drugs need to be readily available if patients are relying on them. Hari is a former corporate finance lawyer & strategy & operations consultant with experience across a wide range of sectors. He left law behind to work across startups within crisis management and consultancy before being inspired by Tom Gray (founder of Blume Jobs) to join the cannabis industry. RESOURCESJoin Hari on Linkedin:https://www.linkedin.com/in/harigulianiGrow Biotech Official Website: https://growbiotech.com/Grow Biotech Twitter: https://twitter.com/growbiotech?lang=enNICE Guidance (Medical Cannabis): https://www.nice.org.uk/guidance/indevelopment/gid-ng10124/documentsBlog post - Does the UK really have medical cannabis?: https://blogs.spectator.co.uk/2019/05/does-the-uk-really-have-medical-marijuana/

Sedan 2012 finns läkemedlet Sativex med medicinsk cannabis i Sverige, men det är inte alla som kan få det. Angela de Cabo vet att hon kommer att dö av sin cancer, men läkarna på Sahlgrenska ville inte skriva ut Sativex till henne. Varför är det så svårt att få den här typen av medicin? GP:s Pia Svensson har träffat Angela de Cabo. Dessutom: Allt vanligare med försenade flyg, kritiserat lagförslag stoppas i Hongkong och Frankrike tänker införa flygskatt. Programledare: Andreas Granath

This Week In Marijuana Business News for the week ended May 10, 2019, with host Nick Thomas. Headlines include: 5 key takeaways from MJBizDaily’s European Cannabis Symposium CBD giant CV Sciences reports $9 million loss in first quarter Cannabis firm Cronos Group misses on revenue, reports wider Q1 loss Epidiolex, Sativex maker GW Pharmaceuticals reports Q1 revenue, loss improvement Chart: Florida medical cannabis market surges ahead, with five companies dominating Texas House OKs second bill to expand medical marijuana qualifying conditions Alabama Senate moves limited medical marijuana program bill forward Ohio panel endorses anxiety, autism as conditions for medical marijuana use Cannabis business win/loss scorecard in Golden State’s legislative session Schumer to reintroduce federal cannabis reform bill Netherlands prepares legal recreational cannabis cultivation experiment Most state attorneys general back cannabis banking reform; treasurers warming What can cannabis learn from the tech industry? Q&A with ex-Yahoo CEO and current Caliva chair Carol Bartz Subscribe to both of our podcasts on iTunes, Stitcher and here on our site!

NM Sativex 23/10/2018

Mr. Tomc is the Vice President of Human Nutrition at CV Sciences. He is a recognized authority on dietary supplements, with twenty years of experience in the nutritional health industry. Formerly the Vice President of North American Herb and Spice, where he served for 10 years, in addition to his service as Global Educator for omega-3 market leader, Nordic Naturals, Mr. Tomc is known for his extensive print interviews and contributions to noted books on integrative medicine, as well as his 4,000 radio appearances. A renowned educator, Mr. Tomc recognizes CBD and its multiple mechanisms of action to support human health, and envisions a new category of dietary supplements derived from agricultural hemp. Topics: 2:35 - From Omega 3 to CBD 4:30 - Eicosanoids and endocannabiods 8:15 - Who is CV Sciences? 12:00 - Regulatory status of CBD and hemp 17:20 - Who is the US Hemp Roundtable 21:14 - Over-the-Counter CBD products 23:35 - Marijuana-dervied CBD 26:35 - Great efficacy w/ terpenes? 29:30 - Isolated CBD v. whole-spectrum CBD 40:00 - Sativex v. Dronabinol 41:00 - Toxicology & safety of hemp extracts 44:00 - GRAS designation 50:00 - NOAEL (No-observed-adverse-effect level) 54:00 - Rescheduling of CBD 60:00 - Regulatory status of CBD post-Epidiolex Studies mentioned in this podcast: Appraising the “entourage effect”: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol An Assessment of the Genotoxicity and Subchronic Toxicity of a Supercritical Fluid Extract of the Aerial Parts of Hemp

In this week’s weed news we talk about #MMJGRANDMA, #PHARMACANN, #INDIANA, #PETCBD, and #GWPHARMACEUTICALSWelcome to Weekly Weed News 2.0 the Podcast with Kief Preston, where I bring you the week’s most important news about weed, medical marijuana, recreational marijuana, cannabis legalization and anything else to do with the good herb – all while smoking on some good!This show was created to raise awareness about cannabis-related issues and motivate people to do something to help the movement and make marijuana legalization a reality as soon as possible. There are so many people we can help and there’s so much money to be made, not to mention all the people locked up that shouldn’t be.“Take Action Today to Help Legalize Weed Tomorrow” -Kief PrestonSTART HERE: kiefpreston.com/Wanna GROW? Free GROW BIBLE – https://bit.ly/2podIAgCBDPET... it's CBD for your pet! - https://bit.ly/2JdtDtoIf you enjoy my content please leave a comment, ask a question, like it, share it, and subscribe for more! It will help me grow my blog and motivate more people to stand up for cannabis and start enjoying its’ many benefits.Stay UP! -Kief▶ STEEMIT steemit.com/@kiefpreston.com▶ Pinterest – pinterest.com/kiefpreston▶ Youtube Channel – bit.ly/2GPQg64▶ Kief Preston’s Time-Tested Edibles Cookbook Series bit.ly/2EXIwAZ▶ My website KiefPreston.com▶ You can also support the cause by shopping on Amazon for ANYTHING you need using this link amzn.to/2GrxPogMore FIRE TRACKS from LMR & Mr Go Hard bit.ly/2plIWbe▶ Hear me on Smoke Radio here: bit.ly/2JTCgJw》》》Check out the Weekly Weed News 2.0 Podcast on Spreaker: bit.ly/2HjLf99 or on Itunes, Stitcher, Soundcloud, iHeartRadio AND nOw on Spotify!

In this week’s weed news we talk about #MMJGRANDMA, #PHARMACANN, #INDIANA, #PETCBD, and #GWPHARMACEUTICALSWelcome to Weekly Weed News 2.0 the Podcast with Kief Preston, where I bring you the week’s most important news about weed, medical marijuana, recreational marijuana, cannabis legalization and anything else to do with the good herb – all while smoking on some good!This show was created to raise awareness about cannabis-related issues and motivate people to do something to help the movement and make marijuana legalization a reality as soon as possible. There are so many people we can help and there’s so much money to be made, not to mention all the people locked up that shouldn’t be.“Take Action Today to Help Legalize Weed Tomorrow” -Kief PrestonSTART HERE: kiefpreston.com/Wanna GROW? Free GROW BIBLE – https://bit.ly/2podIAgCBDPET... it's CBD for your pet! - https://bit.ly/2JdtDtoIf you enjoy my content please leave a comment, ask a question, like it, share it, and subscribe for more! It will help me grow my blog and motivate more people to stand up for cannabis and start enjoying its’ many benefits.Stay UP! -Kief▶ STEEMIT steemit.com/@kiefpreston.com▶ Pinterest – pinterest.com/kiefpreston▶ Youtube Channel – bit.ly/2GPQg64▶ Kief Preston’s Time-Tested Edibles Cookbook Series bit.ly/2EXIwAZ▶ My website KiefPreston.com▶ You can also support the cause by shopping on Amazon for ANYTHING you need using this link amzn.to/2GrxPogMore FIRE TRACKS from LMR & Mr Go Hard bit.ly/2plIWbe▶ Hear me on Smoke Radio here: bit.ly/2JTCgJw》》》Check out the Weekly Weed News 2.0 Podcast on Spreaker: bit.ly/2HjLf99 or on Itunes, Stitcher, Soundcloud, iHeartRadio AND nOw on Spotify!

Transcript for the show is found below the pic: In this episode we are first have a forum discussion covering the terms used in medical cannabis.  The PodcastDX co-hosts will talk briefly about the terminology to familiarize you with some of the terms.  Then we move directly into an interview with a patient who has recently been prescribed medical cannabis.  We get some background into how a new patient goes about applying for and finally obtaining the product for use.  In Illinois this is not as simple as your doctor sending a prescription over to the local pharmacy as you will see.   In the next episode we speak with Dr. Bob Weil, a sports doctor, and Alex, a local budtender at a dispensary.   Episode 12 Medical Cannabis Part One (online-audio-converter.com).mp3   Ron [00:00:16] Hello and welcome to PodcastDX. The show that brings you interviews with people just like you whose lives were forever changed by a medical diagnosis.   Lita [00:00:25] I'm Lita.   Ron [00:00:26] I'm Ron.   Jean [00:00:27] And I'm high on life.   Lita [00:00:29] Or Jean.   Jean [00:00:31] Oh yeah that too.   Lita [00:00:32]  we're collectively the hosts of podcast d x.   Jean [00:00:36] This podcast is not intended to be a substitute for professional medical advice diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider for any questions you may have regarding a medical condition or treatment and before undertaking a new health care regime. Never disregard professional medical advice or delay in seeking it because of something you have heard on this podcast.   Ron [00:01:01] Today's show on medical marijuana is broken down into segments. First we're going to quickly run through a bit of terminology and general information about cannabis. Then we'll interview Meg a patient for whom medical marijuana was recently prescribed.   Jean [00:01:15] The term medical marijuana or a medical cannabis as it's referred to in Illinois refers to using the whole unprocessed marijuana plant or its basic extracts to treat symptoms of illness or other medical conditions.   Lita [00:01:31] Although 28 states and at least one territory have legalized medical cannabis the U.S. Food and Drug Administration FDA has not recognized or approved the marijuana plant as medicine. However the scientific study of the chemicals in marijuana called cannabinoids has led to at least two FDA approved medications that derived from the cannabis plant little hype, or hypocritical there. Additionally prescription medications derived from cannabis and synthetic forms of cannabinoids are available in other countries. The FDA requires carefully conducted studies called clinical trials in hundreds to thousands of human subjects to determine the benefits and risks of a possible medication. So far researchers haven't conducted enough large scale clinical trials that show that the benefits of the marijuana plant as opposed to its cannabinoid ingredients outweigh its risks in patients. It's meant to treat CBD based liquid drug to treat certain forms of childhood epilepsy is being tested in clinical trials but isn't yet FDA approved.   Ron [00:02:53] There are many chemicals in the plants that we use as medicine.   Lita [00:02:57] Examples; morphine, codeine, nicotine, quinine, caffeine, atropine, willow bark, aspirin just to name a few.   Ron [00:03:07] Nicotine is a medicine.   Lita [00:03:08] Well that's another whole subject but yes it can be.   Ron [00:03:12] Nabiximols or Sativex is just one prescription medication that was derived from the cannabis plant. It is an aerosolized mist for oral administration and contains a near 1 to 1 ratio of CBD and THC.   Jean [00:03:26] OK before we get into what CBD and THC are let's run through a few basics Cannabis Sativa is an annual herbaceous flowering plants. Originally indigenous to Asia there's a bit of a controversy in terms of the scientific classification for our purposes. There are three subspecies of cannabis cannabis sativa cannabis indica and cannabis ruderalis and I may not pronounce it correctly. Each of these subspecies has its own characteristics.   Lita [00:03:59] Right Sativa strains are thought to be invigorating improve energy increase focus they tend to have a spicier and sweet smell. Generally they have a higher THC to CBD ratio.   Ron [00:04:14] On the other hand indica strains are thought to have a more sedative effect. They're said to reduce nausea increased appetite have a more skunky scent and typically have a higher CBD to THC percentage.   Lita [00:04:30] As with most things to learn about a subject you need to learn the specialized language and terminology associated with the subject. When it comes to cannabis medical or otherwise there are some terms that are good to know.   Jean [00:04:43] For example we've been mentioning CBD which is ummm cannabidiol which lacks the intoxicating effects of THC.  Unlike THC, CBD is cannabinoid I can say that one that doesn't make people high. It may be useful in reducing pain and inflammation controlling epileptic seizures and possibly even treating mental illness and addictions.   Lita [00:05:08] So CBD is a good one.   Jean [00:05:10] Well yeah.   Lita [00:05:11] Well.   Jean [00:05:11] There. Yeah.   Lita [00:05:12] Yeah. Not as much of a high.   Jean [00:05:15] no, Yeah. It's not meant to give you a high.   Lita [00:05:16] It's only for the medicinal.   Jean [00:05:18] Right. Or that intoxicating effect.   Lita [00:05:20] Got it.   Lita [00:05:21] The body also produces its own cannabinoid chemicals. They play a role in regulating pleasure, memory, thinking, concentration, body movement, awareness of time, appetite, pain, and the senses like taste, touch, smell, hearing, sight.   Jean [00:05:38] Right and THC which is a tetra hydro cannabinol THC is a lipid and it's finding cannabis THC can increase appetite and reduce nausea and it also can reduce or decrease pain and inflammation such as swelling and redness too and it can help with muscle control problems.   Ron [00:06:00] And intoxication is defined as a temporary state of diminished physical and mental control. Some typical intoxicating agents or alcohol liquor certain drug or other substances.   Jean [00:06:17] Right. So we said like THC has an intoxicating effect.   Lita [00:06:21] Right.   Jean [00:06:21] OK.   Lita [00:06:22] So the term mind altering refers to chemicals which produce mood changes or which give you a sense of heightened awareness.   Jean [00:06:32] OK. And to wrap our segment up psychoactive chemicals are substances which have a profound or significant effect on the mental processes.   Ron [00:06:42] You can take medicinal cannabis orally topically trans dermally or sub lingually  which is under the tongue or can be inhaled. Allow me to introduce Meg.  Meg is an artist who resides in Illinois. She has recently been prescribed medical marijuana.   Jean [00:07:01] Hi Meg.   Lita [00:07:03] Hi Meg.   Meg [00:07:03] Hi.   Lita [00:07:03] In some states you simply need to take your state issued I.D. card and a prescription to a dispensary in order to obtain medical cannabis. Is that the case in Illinois.   Meg [00:07:12] Not exactly the medical cannabis patient registry program allows people who are diagnosed with a debilitating medical condition and their caregivers to register with the Illinois Department of Public Health in order to obtain access to the cannabis for medical use. So in Illinois you need to apply for the medical cannabis registry I.D. card.   Lita [00:07:31] Oh ok.   Ron [00:07:32] Well how does somebody apply for the I.D. card.   Meg [00:07:34] There are five basic routs to which you can apply for the card. The process is a bit different for terminal patients minors and for veterans who are receiving treatment at a V.A. facility.   Jean [00:07:45] And you don't fall into any of those categories do you know.   Meg [00:07:48] No, I am in the third category of everyone else.   Ron [00:07:51] So what's the process like for everyone else.   Meg [00:07:54] Well you can either work through the paperwork on your own contact the center or your local health department for assistance to complete the process.   Lita [00:08:02] And what is that process like.   Meg [00:08:04] I went to with a company that walks you through the process. I had my first appointment with a physician on January 30th and from there I had to do a video appointment which I had on February 5th. The average wait time to receive the card once in the mail. Once you've completed all your paperwork is about eight to twelve weeks and mine took twelve weeks so I got my medical cannabis registry ID card on April 16.   Jean [00:08:27] OK. So it can take a while to have your paperwork processed by the state.   Meg [00:08:31] If you're working on the paperwork on your own it's a bit more complicated. First of all in Illinois you have to be a resident in Illinois.   Jean [00:08:38] The first rule of Fight Club is you don't talk about fight club.   Lita [00:08:41] OK. Go ahead Meg   Meg [00:08:42] You can not have any prior felony drug convictions. You cannot be a firefighter correctional officer active duty law enforcement officer or correctional probation officer. If you have a permit to drive a school bus or CDL you're not eligible for the current state program. And of course you must be diagnosed with the qualifying condition.   Jean [00:09:01] But you can you know,. That's not excluding too many things.   Lita [00:09:06] Ummm yeah laughing.   Jean [00:09:06] How can someone find out if they have a qualifying condition.   Meg [00:09:09] In Illinois you can find a list of qualifying conditions on the Illinois Department of Public Health web site which is a DPA. Illinois gov.   Ron [00:09:17] OK all right so what's next.   Meg [00:09:21] In Illinois you need to be a you need a physician licensed in the state of Illinois to complete the three page physician written certification form and here the states instructions are a bit hazy.   Jean [00:09:32] How do you mean.   Meg [00:09:33] Well on the physician written certification form it says the completed sign forms should be given to the patient and submitted along with their other paperwork by the patient.   Lita [00:09:42] OK.   Meg [00:09:43] But in the application for qualifying patient registry ID card instructions it states that the physician should complete their portion of the paperwork and mail it directly to the IDP wages Division of Medical Cannabis.   Lita [00:09:57] That's conflicting so within what's next.   Meg [00:09:59] You need to complete the applications form selected dispensary and fill out the medical cannabis dispensary selection form. Pay an application fee which varies from 50 to 250.   Lita [00:10:10] ohhh.   Meg [00:10:10] Mail the completed forms along with a color copy of your Illinois state and federal. Issued I.D. color photographs similar to a passport photo. A copy of two documents let establish your residency like utilities bills and leases and get a fingerprint based background check and submit the receipt for the fingerprint scan along with everything else to the DP H.   Lita [00:10:32] huhhh wow, the grass is certainly greener in states that only require a state I.D. and a prescription.   Jean [00:10:37] But-tum bum.   Lita [00:10:39] laughter.   Jean [00:10:39] Yeah you do the hokey pokey.   Ron [00:10:41] So then you take your card to the dispensary and pick up your medical cannabis.   Meg [00:10:46] Yeah. Basically I'm allotted two and a half ounces every two weeks so they keep track of it on their computers. What I've purchased. How much. The amount is and it tracks the weeks.   Jean [00:11:01] OK sure. Sure.   Lita [00:11:03] See I'm exhausted just hearing about the process. I mean seriously that's a lot of steps to go through.   Ron [00:11:09]  It's the state of Illinois.   Lita [00:11:10] Illinois. Yeah I get us has the medical cannabis help ease the symptoms of your medical condition.   Meg [00:11:17] Yeah I part of why I started to do it was I was having trouble sleeping and with my doctor we decided that the first priority would be to get me a full night's sleep.   Jean [00:11:29] That sounds nice.   Meg [00:11:30] It would be beneficial especially since at the time I was going through my final call my semester.   Lita [00:11:35] Finals  in college yeah.   Meg [00:11:36] And no sleep would be very nice.   Jean [00:11:38] Yeah!   Meg [00:11:38] . And then from there it also just it helps with my pain, my depression and anxiety. I mean just kind of everything I call it the wonder wonder wonder plant.   Jean [00:11:48] Great.   Lita [00:11:49] Right now. Yeah.   Ron [00:11:50] Glad to hear that. Thank you for joining us today Meg and for the insight into this incredibly difficult application process in the state of Illinois.   Jean [00:12:00] Yeah. Thank you Meg.   Lita [00:12:01] That wraps up Part 1 of 2 for our podcast about medical cannabis. Join us next week when we'll interview Dr. Weil and get a physician's view of cannabis as medicine.   Jean [00:12:14] If our listeners have any questions or comments related to today's show they can contact us at podcast D X at yahoo dot com through our Web site Podcast DX  dot com, on Facebook, Twitter, Pinterest or Instagram.   Lita [00:12:32] And if you have a moment to spare please give us a five star review on the iI tunes podcast app.   Jean [00:12:38] And we'd like to think those of you who have already done so. Till next week.   Lita [00:12:42] Bye bye.  

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Takeda, Shire, Syngenta Nuove terapie: Sativex, Ocrelizumab, NivolumabPatologie: Malattia di Huntington, Malaria, Spasticità post-ictus, Sclerosi multipla, HCV, Melanoma avanzato, Carcinoma a cellule renali avanzato Lavoro: Quality Assurance Manager, Global Clinical Team Lead, Clinical Research Associate Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Takeda, Shire, Syngenta Nuove terapie: Sativex, Ocrelizumab, NivolumabPatologie: Malattia di Huntington, Malaria, Spasticità post-ictus, Sclerosi multipla, HCV, Melanoma avanzato, Carcinoma a cellule renali avanzato Lavoro: Quality Assurance Manager, Global Clinical Team Lead, Clinical Research Associate Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

Today on Hempire Dr. Eileen Karpfinger is joined by Dr. Ester Aso. Dr. Aso has been working on the potential utility of cannabinoids for treating AD during the last 8 years. She has obtained promising results in animal models of the disease, suggesting that the combination of THC and CBD 1:1 at very low doses might reduce the progression of the disease. Now Dr. Aso setting up a phase II clinical trial funded by the Alzheimer's Association (USA) with Sativex in patients in the very early stages of the AD (mild cognitive impairment). She still has no date to the start of the recruitment period, but hopes it will be completed during 2018. It will be a small trial, with only 60 patients, but will give her primarily information about the safety and tolerability of this drug in this specific population and, secondarly, some evidence about its efficacy in halting the progression of the disease.

[intro music]   Host – Dan Keller Hello, and welcome to Episode Ninety-seven of Multiple Sclerosis Discovery, the podcast of the MS Discovery Forum. I’m Dan Keller.   Today's interview features Dr. David Baker, Professor of Neuroimmunology at Queen Mary University of London in the UK. We spoke at the ECTRIMS conference last fall, where I asked him about his work with cannabinoid compounds – work that has led to a better understanding of the cannabinoid system as well as to candidate drug compounds to treat spasticity.   Interviewer – Dan Keller In terms of what you're doing now with cannabinoids, can you tell me what you are looking for, and what you've found?   Interviewee – David Baker Many, many years ago, we actually were probably the first people to show that cannabis can actually alleviate muscle stiffness in animal models of multiple sclerosis, which then kind of underpinned the push to look for cannabis in MS. So people with MS were smoking cannabis and perceiving benefit. The question was, why? And what they didn't really understand that there was going to be an unfolding biology. And a few years later after our first discovery that actually cannabinoids can cause relaxation of the muscles, we understood that the function of the cannabinoid system is to regulate nerve signaling. And so because the cannabinoid system does regulate the strength of synaptic signaling, then it's obvious that it can inhibit signs and symptoms because of this excessive neurostimulation. So at the time of that, then we realized that the receptor is a CB1 receptor, and the compound within cannabis is THC, and they're the same molecules that cause all the side effects. So you could never really disassociate away the high from the medical benefit. So we started to think, well, how can we try and get the medical benefit from the cannabinoid system and at the same time try and limit the side effect potential.   So what we thought is, well, if we can stop the cannabinoid molecules getting in the brain, then they won't cause the side effects. But maybe we can target the aberrant signaling in the spinal cord and the peripheral system to try and get the benefits. And so that was our intention. So we tried to make a CNS-excluded drug. And that's, in fact, what we did. We made a drug that was very, very water soluble, so you know, you use the mechanism of the blood-brain barrier to actually exclude it from the brain. So we made the compound, and a few weeks later, we kind of started putting it into animal models, not really doing it the pharmaceutical way, which would be a methodical testing. So we showed that it didn't cause any of the unwanted side effects that are associated with cannabis in the animals. And then we put it in a system where we had a spasticity in a multiple sclerosis relevant system, and the drug worked.   Now what we did know is that the drug was blocked by the activity of the CB1 receptor antagonist, so it looked like we'd made what we set out to make. So we were really excited. And from that point, we started to try and see if we could develop it as a drug. Unfortunately what we realized very quickly actually is that it doesn't work by the known cannabinoid receptor system, and I think what we stumbled across is a whole new biology of the cannabinoid system.   And so we've been developing this drug bit by bit. We set up a university spinout company to try and develop it as a pharmaceutical drug. And over the years, bit by bit, we've been pushing it forward. So it's very safe in animals. It has a massive therapeutic window. And with grant funding agencies etc. we've managed to be able to take it into phase I study where it passed with flying colors. We tested it in 60 healthy humans. And a few weeks ago, we started our first testing in people with multiple sclerosis. So we'll have to see how it works. But we hope by early in 2016 we'll have the answer. So it could be a symptom modifying drug, but it doesn't have any of the side effects associated with drugs such as, you know, Sativex or baclofen as well. So it's not sedating as far as we know.   The way that the drug works is a new mechanism. And what we can probably say is it serves to block the excitation of nerves. So it dampens down excessive signaling, which are probably the consequences or the causes of spasms and spasticity and possibly the symptoms as well and maybe pain. We just have to do more work to see if it will work that way.   MSDF Is this a hyperexcitable system? Or is it a hypoinhibited system where you're getting this spasticity?   Dr. Baker Well, I think spasticity is largely caused by loss of the inhibitory circuitry. So there's probably less GABAergic signaling. And so one can, you know, drive the inhibitory system, like you do with GABA, but likewise you can actually kind of block the excitation. And this mechanism actually probably only exists in pathology. So this is probably why there isn't the side effect potential that the real target that we're actually after really only occurs when the nervous system is going a bit haywire. So that's why we think we've got good safety margin.   MSDF And you had told me that this does not induce hunger, which I guess is another sign that it's not getting into the CNS?   Dr. Baker Having said all that, it was made not to get in the central nervous system, but in reality, it doesn't matter if it does get in the central nervous system. So in fact, about 15% of the drug does get into the central nervous system, which would be as good as many drugs that are CNS penetrant. I guess when we were starting, we were hoping that, you know, it was going to be excluded because we thought it was a cannabinoid receptor agonist, but in reality, it doesn't matter. And in fact what we know is actually this targeting into the lesions. So there's actually more goes into the area. And what this kind of spins on to some other work that we've done with some of our sodium channel work.   We've been developing new sodium channel blockers as potential neuroprotectants. And what we've done is certain molecules actually get excluded by CNS drug pumps, and what we'd noticed in MS is that some of these drug pumps disappear. So we made a drug that was actually targeted specifically to one of those drug pumps, which would normally mean it would be excluded from the brain, but what we showed is that with these new sodium channel blockers, that actually they physically target into the lesion where the pump disappears. And so again, you increase this therapeutic window between effect versus side effect, because again with the sodium channels, you need them for health. You block them, and you have side effects. But what we've found with the sodium channel blockers is that in the animal models, sodium channel blockers were neuroprotective, and we then took that idea forward actually into the clinical trial.   So we first of all thought the trials with sodium channel blockers had failed. Why had they failed? Well, the reason they failed was the trial outcomes weren't right, and suddenly actually because of this unpleasant side effect, 50% of the people didn't take the drug. So the trial was doomed before it ever started. And then what we had was we had the bloods of the people in the trial. So we looked two years after the trial had finished and was seen to be a failure, and we found that 50% of people weren't taking the drugs. But if you look to the people who were taking the drugs, we could see that there was less neurofilament in their blood indicative that there is less nerve damage. And so actually in reality, the trial actually was positive, but it was seen to be negative because of this failure to take the drug.   So the question was, how could we then develop that forward? So the clinical guy said, well, let's think how we could best do a quick trial. And they came up with the idea of the optic nerve being the ideal target. And so what they said to us was, can you, you know, model this in the animal model? So we developed a new animal model. So we took Vijay Kuchroo's 2D2 mice, which are preprogrammed to get optic neuritis, and then we just made their eyes florescent so we could just look in their eyes and see nerves in real time and in life. And as a consequence of using the transgenic, which targeted myelin oligodendrocyte glycoprotein, the cells would go in, cause optic neuritis, that would cause nerve death, and then we could monitor the nerve death just by looking into the eye, because each nerve was labeled with a fluorescent protein. We'd see one single nerve die.   And so we started to use that as a way of testing different drugs for neuroprotection. And we put a whole stack of different compounds, minocycline, sodium channel blockers, glutamate receptor antagonist, we did a few. And we got some hits with the sodium channel blockers, and we tried a few of the different ones, some of them better than others. And unfortunately the one that they chose for the trial is probably the worst one in the animals, but they decided that you had to load drug quickly, so they selected phenytoin. So we showed that the sodium channel could work in the optic neuritis, and then the idea was then we translate that and then do a trial with optic neuritis in the human.   So this was a trial that Raj Kapoor did. And so the idea was that people go blind, and then you go to the doctors. And then they were randomized to either get steroids, which is the standard treatment, or they'd get steroids plus a sodium channel blocker, which was phenytoin at the time. And that was done because you can dose very quickly. So the idea was to get people on drug very quickly. So within seven days of their first symptom, people were on active drug. And people were treated for about six months. And then they looked at the retinal fiber thickness. So as a consequence of the ganglion in the retina dying, the retina thins, and then you can measure that with a machine called OCT, optical coherence tomography. And that was slowed. So they saved 30% of the nerves from dying, even though there were people getting a steroid. So it tells us that really certain channel blockers are neuroprotective.   And then the question is, is how then can we show that in reality? So what we've done from there is we've actually gone on with another sodium channel blocker, which was called oxcarbazepine, which was much more effective in the animal models. And we've been trying to initiate a new trial design whereby we're looking for people who are on current DMTs by showing evidence of neurofilament release, which is indicative that their nerves are being destroyed, because as the nerves are destroyed, they liberate their contents, and then we can pick that up in the biological fluids. So the idea is that if they've got neurofilaments in their cerebrospinal fluid, they get the option of having a sodium channel blocker in addition to their DMT. And then we'll monitor them by serial lumbar punctures to see if the neurofilament levels decrease as a way of a trench push on the trial design for phase II.   Because if you're thinking about the standard phase III, phase II trial for neuroprotection, you're talking about a two- or three-year trial, which will take you two years to recruit the 600 people and another year to do the analysis. So you're really talking about a seven-year trial with 600 people. This trial design will kind of push it down probably to 12 months to 18 months with 60 people. So we can do 10 times more people and a lot quicker this way. So that's started where we've been recruiting, and we're still recruiting, but fingers crossed that would be another way forward in terms of developing neuroprotection. I think it shows how we've been trying to use our animal models to translate things into the human. Because at the end of the day, there has been really, really poor translation between the animal models and humans. And I guess the question is, is why?   MSDF We’ll pick up on that question in part two of our interview with Dr. Baker next time, when he’ll describe some of the deficiencies he sees in the design and interpretation of animal experiments and how they could be improved to better relate to clinical trials and the clinical situation.   [transition music]   MSDF Thank you for listening to Episode Ninety-seven of Multiple Sclerosis Discovery. This podcast was produced by the MS Discovery Forum, MSDF, the premier source of independent news and information on MS research. Msdiscovery.org is part of the nonprofit Accelerated Cure Project for Multiple Sclerosis. Robert McBurney is our President and CEO, and Hollie Schmidt is Vice President of Scientific Operations.   Msdiscovery.org aims to focus attention on what is known and not yet known about the causes of MS and related conditions, their pathological mechanisms, and potential ways to intervene. By communicating this information in a way that builds bridges among different disciplines, we hope to open new routes toward significant clinical advances.   [outro music]   We’re interested in your opinions. Please join the discussion on one of our online forums or send comments, criticisms, and suggestions to editor@msdiscovery.org.   For Multiple Sclerosis Discovery, I'm Dan Keller.

When the acceptance of medical cannabis goes mainstream, the pharmaceuticals landscape will face the most significant disruption of its existence. Due to the federal classification of marijuana as a Schedule 1 controlled substance, researching possible medical uses for the plant has been difficult. However, this has not stopped some companies from conducting their own research and clinical trials of cannabis medicines. Our latest podcast interview features Dr. Ethan Russo, formerly Senior Medical Advisor to GW Pharmaceuticals, who participated in three clinical trials of the drug Sativex. Dr. Russo recently left GW Pharmaceuticals and can now speak publicly for the first time about his research: up until now, he could only be heard at expensive, exclusive conferences. He is now Medical Director at Phytecs, a company specializing in the production of cannabis-based treatments related to the endocannabinoid system. Everything that contemporary cannabis healers talk about in relation to cannabis as medicine is based on Dr. Russo's published research, including the power of cannabis terpenes, the Entourage Effect, and Endocannabinoid Deficiency. In this interview, our host Shango Los asks Dr. Russo about Endocannabinoid Deficiency (ECD) and the potential for it to be treated by cannabis. All human beings have an endocannabinoid system, which, according to Russo, regulates nearly every aspect of physiology. Endocannabinoid Deficiency is just coming into general awareness now as a cause behind several conditions including Migraines, Fibromyalgia, Irritable Bowel Syndrome, Phantom Limb Pain, Infantile colic, Glaucoma, PTSD, Bipolar disease and others. If cannabis becomes accepted by the mainstream medical community as a treatment for ECD and its associated conditions, the implications for the pharmaceuticals market would be staggering to say the least. Listen to the podcast or read the transcript below to learn about the science behind ECD and how cannabis can be used as a treatment. For a full transcript: https://www.ganjapreneur.com/ethan-russo-endocannabinoid-deficiency-medical-cannabis/

Today in FirstWord:

Under steinbittfiske i 2006 skjedde ulykka. Ei kraftig bølge traff fiskebåten Joachim bløda fisk på, og han fikk bløderkniven i låret. Den tynne kniven traff en nerve. Smertene blei konstante og voldsomme. Joachim har nå 6-7 i smerter på en skala fra 1-10. Beveger han seg for mye kan smertene komme helt opp i 10. Han har prøvd mange forskjellig medisiner. Paralgin Forte, Sarotex, Lyrica, Lipiderm-plaster, chilikrem og cannabismunnsprayen Sativex. Ingen har klart skikkelig å døyve de konstante smertene. Det eneste han mener har fungert er det nederlandske medikamentet Bedrocan, en medisinsk cannabis som det nederlandske helsedepartementet eksporterer til ulike land i Europa. Men ikke til Norge. En dokumentar av Webjørn S. Espeland.

Under steinbittfiske i 2006 skjedde ulykka. Ei kraftig bølge traff fiskebåten Joachim bløda fisk på, og han fikk bløderkniven i låret. Den tynne kniven traff en nerve. Smertene blei konstante og voldsomme. Joachim har nå 6-7 i smerter på en skala fra 1-10. Beveger han seg for mye kan smertene komme helt opp i 10. Han har prøvd mange forskjellig medisiner. Paralgin Forte, Sarotex, Lyrica, Lipiderm-plaster, chilikrem og cannabismunnsprayen Sativex. Ingen har klart skikkelig å døyve de konstante smertene. Det eneste han mener har fungert er det nederlandske medikamentet Bedrocan, en medisinsk cannabis som det nederlandske helsedepartementet eksporterer til ulike land i Europa. Men ikke til Norge. En dokumentar av Webjørn S. Espeland.

PatiCakes, Queen of Cannabis; Mr B, Not a Tech God Today; Patrick Moore AKA Dr Mesmer, Health Freedom Activist & Eminent Hempster; Jeanette, Hemp Educator talk Hemp Education, BioFuels & Hemp as the Valuable resource that it is.......... Naples Italy: Published online in the Journal of Molecular Medicine, Italian study finds non-psychotropic Cannabinoid inhibits Colon Cancer cell proliferation! Patrick Moore, AKA, Dr Mesmer hemptucates us regarding Bio-fuels, Hemp Farming & talks about His Mercedes Benz that runs on Hemp Fuel............... Movies/Documentaries to watch: Bringing it Home,The Emperor Wears no Clothes, BBC Horizon: A look at MedicalCannabis & Sativex, Sean (1970) and many more........... Hemp is used for Food, Fuel, Paper Products, Textiles, MouldedPlastics, Body Care Products, Animal Feed, Nutritional Supplements, Medicines, etc............... Hey Nike Makes Hemp Nikes!!! Yea! Hemp industry achieves goal of US hemp-made flag: Despite the failing of the Federal farm bill last month to allow U.S. farmers to raise Industrial Hemp, hemp leaders and activists were overjoyed as the American flag, made of industrial hemp, flew over the U.S. Capitol. Hemp has untapped market as biofuel, Pikeville businessman says http://www.kentucky.com/2013/02/26/2532443/hemp-has-untapped-market-in-biofuels.html#storylink Hemp has untapped market as biofuel, Pikeville businessman says http://www.kentucky.com/2013/02/26/2532443/hemp-has-untapped-market-in-biofuels.html#storylink www.hempradio.com Check out Patrick on twitter/facebook @drmesmer www.normalwomensalliance.org A big shout out to all our Hemp Friends!! We love you!! Contact me at: paticakes@hempradio.com

The Daily Dabber aka Justin P and I sit down for a chat at The Coast Collective in San Diego. We talk Talk Lauren Duffy, Marijuana Dispensaries, Re Election Years, Sativex, C.B.D.'s, Natures Interest Psychoactivity, Weeds Track Record, Legalization, Oil and Drugs, LSD in The Water Supply, Botany of Desire, Occupy SD, Participatory Democracy, and Subconscious Preparations